Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12467552 | 0.96 | CTSK (0.34) | CTSKLMNAPSMB5METAP2CTSS | |
| SCHEMBL14943361 | 0.84 | CTSK (0.38) | CTSKLMNAPSMB5CTSSMGLL | |
| SCHEMBL12401173 | 0.83 | CTSK (0.37) | CTSKLMNAPSMB5CTSSMGLL | |
| SCHEMBL12486464 | 0.83 | HDAC3 (0.38) | HDAC3HDAC1HDAC2CNR1CNR2 | |
| SCHEMBL12401107 | 0.82 | CTSK (0.38) | CTSKLMNAPSMB5METAP2CTSS | |
| SCHEMBL8241710 | 0.81 | CTSK (0.35) | CTSKLMNAPSMB5CTSSMGLL | |
| SCHEMBL12636348 | 0.81 | LMNA (0.41) | LMNAHDAC3HDAC1HDAC2CNR1 | |
| SCHEMBL12467540 | 0.80 | EPHX1 (0.51) | EPHX1HDAC1 | |
| SCHEMBL12401303 | 0.80 | HDAC3 (0.35) | CTSKLMNAMGLLHDAC3HDAC1 | |
| SCHEMBL12467539 | 0.80 | EPHX1 (0.51) | EPHX1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | CTSK 240/4885LMNA 2850/4885PSMB5 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.